Amit Sachdev
Neurology · East Lansing, MINPI 1962720797
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $240,804 of the $374,319 with a category attached, or 64.3%. 50 manufacturers reported payments, led by AstraZeneca at 38.9% of the total. 2025 is the largest year on record at $146,935, 7.3 times the $20,199 reported in 2019. Among neurology clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 512 payments — averaging $731.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$146K
- Argenx US, Inc.$64K
- UCB, Inc.$55K
- Amgen$43K
- CSL Behring$23K
- Sanofi$16K
- plus $26K from 44 others
Across 501 payments — averaging $2514.49 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eisai Inc.$788K
- UCB SA$227K
- Sanofi US Services Inc.$69K
- Argenx US, Inc.$67K
- AstraZeneca$48K
- Takeda Pharmaceuticals U.S.A., Inc.$24K
- plus $38K from 3 others
What the payments were for
- Consulting fees$68,62318%
- Speaking & faculty fees$240,80464%
- Grants$290%
- Travel & lodging$53,51014%
- Food & beverage$11,2653%
- Education$890%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$374,319 in reported general payments places this provider in the 95th percentile of 652 neurology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SolirisEculizumab | 47 | $2,449,238 |
| GammaplexImmun Glob G(Igg)/Gly/Iga 0-50 | 79 | $1,033,881 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 73 | $773,539 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 68 | $581,903 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 26 | $170,850 |
| Pyridostigmine Bromide | 118 | $24,652 |
| Pyridostigmine Bromide ErPyridostigmine Bromide | 30 | $17,490 |
| Mycophenolate Mofetil | 43 | $6,909 |
| Gabapentin | 143 | $2,428 |
| Levetiracetam | 31 | $1,353 |
| Pregabalin | 49 | $1,281 |
| Duloxetine Hcl | 58 | $1,031 |
| Prednisone | 102 | $1,005 |
| Donepezil Hcl | 28 | $940 |
| Baclofen | 29 | $814 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaSoliris | $145,621 | $2,449,23847 claims |
| CSL BehringPrivigen | $23,243 | $773,53973 claims |
| Grifols USA, LLCGamunex-C | $28 | $581,90368 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid | $9,776 | $170,85026 claims |
| Amneal Pharmaceuticals LLCPyridostigmine Bromide, Mycophenolate Mofetil | $26 | $31,561161 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 652 neurology providers in Michigan.
Other neurology in East Lansing
- Tariq GheithEast Lansing$347K
- Larry CharlestonEast Lansing$284K
- Jayne WardEast Lansing$169K
- Aaron EllenbogenFarmington Hills$1.6M
- Matthew HoltzmanWayne$1.4M
- Richard TroschFarmington Hills$1.2M
- Wade CooperAnn Arbor$991K
- Bisena BulicaDetroit$900K
- Julie BurnhamMount Clemens$836K
- Amit MasihOkemos$785K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.